Related Experiment Video
Updated: Mar 28, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
New Oral Anticoagulation after Heart Valve Replacement
Ibrahim El-Battrawy1, Stefan Baumann, Aydin Huseynov
1First Department of Medicine, University Medical Centre Mannheim (UMM), Faculty of Medicine Mannheim, University of Heidelberg, Mannheim, Germany; DZHK (German Center for Cardiovascular Research) partner site Mannheim, Mannheim, Germany. ibrahim.el-battrawy@umm.de.
Antithrombotic treatment with vitamin K antagonists remains the standard for mechanical heart valves. Newer oral anticoagulants are not recommended due to higher risks of thromboembolism and bleeding events.
Area of Science:
- Cardiology
- Pharmacology
- Surgical Innovation
Background:
- Vitamin K antagonists (VKAs) have been the gold standard for antithrombotic therapy after mechanical heart valve replacement since the 1960s.
- Newer oral anticoagulants (NOACs) have transformed treatment for atrial fibrillation and venous thromboembolism.
- Current guidelines contraindicate NOACs for mechanical heart valves due to safety concerns.
Purpose of the Study:
- To evaluate the efficacy and safety of newer oral anticoagulants compared to traditional vitamin K antagonists in patients with mechanical heart valves.
- To determine the risk of thromboembolic events and bleeding associated with NOACs in this specific patient population.
Main Methods:
- Review of large clinical trials comparing NOACs and VKAs in patients with mechanical heart valves.
- Analysis of data on rates of thromboembolism, bleeding events, and overall safety profiles.
Main Results:
- Large trials demonstrated significantly higher rates of both thromboembolism and bleeding events with NOACs compared to VKAs.
- NOACs are currently contraindicated for mechanical heart valves based on existing trial data.
Conclusions:
- Current evidence does not support the use of newer oral anticoagulants in patients with mechanical heart valves.
- Further research is necessary to explore the potential role and safety of specific NOACs in this patient group.
More Related Videos
08:50Technique and Patient Selection Criteria of Right Anterior Mini-Thoracotomy for Minimal Access Aortic Valve Replacement
Published on: March 26, 2018
08:42Cox-Maze IV Procedure Concomitant with Valvular Surgery In Situs Inversus Dextrocardia: A Single-Center Experience in China
Published on: February 11, 2022
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Aortic Regurgitation III: Medical Management
Venous Thrombosis IV: Nursing Management
Endocarditis III: Medical Management